Compare GSK plc (GSK) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Marathon Petroleum Corp — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Marathon Petroleum Corp trades at $348.5 (market cap $94.48B). The key difference: GSK plc and Marathon Petroleum Corp are close in size by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | MPC | |
|---|---|---|
Market Cap | $102.60B | $94.48B |
Sector | Health | Energy |
52-Week High | $61.18 | $336.42 |
52-Week Low | $38.22 | $159.11 |
Enterprise Value | $123.04B | $121.00B |
Dividend Yield | 3.57% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Marathon Petroleum (MPC) trades at $345.68, up 7.92% over 24 hours, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with a P/E of 11.67 and ROE of 47.9%, supported by recent earnings beats including Q2 2026 EPS of $17.73 versus $14.27 expected. Refining margins remain elevated due to global supply constraints, driving revenue growth projections to $153.6B for 2026.
MPC presents a compelling investment case with strong cash flow generation and shareholder returns via dividends and buybacks. Key risks include exposure to volatile energy markets and geopolitical factors affecting refining margins. Wall Street maintains strong bullish consensus with 76% buy ratings and $332.70 price target, though current price exceeds consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
